| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 1,194,620 | 1,058,520 | 847,130 | 747,590 | 560,410 |
| Sales Growth | +12.86% | +24.95% | +13.31% | +33.40% | +2.37% |
| Net Income | 14,010 | 90,950 | -2,000 | 5,280 | -15,700 |
| Net Income Growth | -84.60% | +4,647.50% | -137.88% | +133.63% | -132.40% |
Penumbra Inc (PEN)
277.42 +6.29 (+2.32%) 15:59 ET [NYSE]
258.88 x 100 292.33 x 100
Realtime by (Cboe BZX)
258.88 x 100 292.33 x 100
Realtime - - (-) -
for Wed, Apr 2nd, 2025
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
Fiscal Year End Date: 12/31